Tiziana’s nasal foralumab reduces microglial activation in progressive MS trial
Tiziana Life Sciences (TLSA) reported that its nasal foralumab reduced microglial activation in a Phase 2a trial for non-active secondary progressive multiple sclerosis. The 50 microgram dose showed significant reductions on TSPO PET imaging. Both doses improved fatigue, though the study wasn't powered for that endpoint. The company plans to discuss next steps with the FDA.
How this was made

The 30-second read
Why it matters
The trial met its primary endpoint, showing reduced microglial activation on PET imaging and fatigue improvement, suggesting potential disease‑modifying activity.
Market read
First‑time positive data for a microglial‑targeting therapy could drive speculative buying in TLSA and influence the broader neuro‑inflammation sector.
What to watch
Small sample size (19 patients) and lack of long‑term safety data could temper enthusiasm.
Background
Tiziana Life Sciences (NASDAQ:TLSA) announced its first Phase 2a results for nasal foralumab in non‑active secondary progressive multiple sclerosis.
Ticker impact
Nasal foralumab Phase 2a trial showed significant reduction in microglial activation and fatigue improvement in progressive MS patients.
upward pressure as market prices in the favorable efficacy signal.
Early‑stage trial success is material for a biotech; the data are new and the company has no approved therapy, so investors will likely bid the stock.
Market effects
May boost sentiment for neuro‑inflammation and MS therapeutic pipelines.
Limited to US biotech investors; no broader regional effect.
Highlights emerging intranasal antibody approaches, of interest to global biotech community.
Counterpoint
Phase 2a data are early; efficacy may not translate to later stages, risk of failure remains high.
Key entities
- companyTiziana Life Sciences Ltd
Biotech firm developing intranasal foralumab for MS.
- executiveIvor Elrifi
CEO of Tiziana Life Sciences.
